CD274 and esophageal squamous cell carcinoma: We found that, immunotherapy could achieve OS benefits regardless of PD-L1 expression in advanced ESCC but not PFS benefits, that means a lack of PFS benefits did not rule out long-term OS benefits (Supplementary Fig. 5).